FibroGen, Inc.

FibroGen, Inc.

FibroGen, Inc.

Overview
Date Founded

1993

Headquarters

409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158

Type of Company

Public

Employees (Worldwide)

461

Industries

Biotechnology
Pharmaceuticals

Company Description

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at FibroGen, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Executive Director, Clinical Development

Chief Financial Officer

Chief Intellectual Property Officer

Chief Legal Officer

Chief Medical Officer

Chief Medical Officer

Senior Vice President, Drug Development

Senior Vice President, Regulatory Affairs

Senior Vice President, Technical Development

Board of Directors

Interim President at FibroGen, Inc.

Advisory Director at Berkshire Partners LLC

Chief Executive Officer at FibroGen, Inc.

Chairman at Cibus Corp.

Venture Partner Healthcare at Qiming Venture Partners Ltd.

Former President-Asia Pacific at Baxter International, Inc.

President & Director at Grama Ventures LLC

Former Senior Vice President-Global Marketing & Commercial Development at Amgen, Inc.

Former Director, Chief Science Officer & Executive Vice President at Astellas Pharma, Inc.

Former Executive Vice President, Finance & Business Development & Chief Financial Officer at Allergan, Inc.

Paths to FibroGen, Inc.
Potential Connections via
Relationship Science
You
FibroGen, Inc.
Owners & Shareholders
Details Hidden

HCA employs bottom-up analysis and fundamental proprietary research which seeks long-term, risk-adjusted returns through. The firm invests globally with a particular focus on companies or assets having substantial relations with Asia. As part of their bottom-up analysis, they performs both qualitative and quantitative assessments of potential investments with a particular focus on opportunities upon which it can gain insights and discover value in an ever-changing world. HCA generally focuses on publicly-listed (or similarly liquid) investment opportunities across multiple industries, but it may also participate in private (or otherwise less liquid) investment opportunities. The firm invests primarily in reasonably priced companies that provide substantial long-term growth prospects. Although HCA monitors macro-economic factors and market trends, they generally avoid market-timing strategies and focuses primarily on bottom-up opportunities. HCA focuses on understanding fundamental risks, uncovering long-term growth potential, and targeting industries that it understands and can monitor.

Details Hidden

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Details Hidden

Ecor1 Capital manages the EcoR1 Capital Fund LP, a fundamental long/short equity hedge fund focusing on investment opportunities in the biotechnology sector. The firm employs an innovative, process-driven approach that is based on a value philosophy which attempts to manage risk in the volatile biotechnology sector. The fund focuses on outliers not typically analyzed as part of value based diligence; human capital in addition to deep scientific and financial analysis. Ecor1 Capital is committed to going beyond the usual monetary investment in companies and engages directly with management to identify opportunities for efficiencies and growth, and where necessary, invests their own human capital resources to help mediate much of the risk that is inherent in the sector. The goal of combining this innovative perspective and process is generation of uncorrelated returns relative to the biotechnology sector and to the overall market.

Recent Transactions
Details Hidden

FibroGen, Inc. issued USD Common Stock

Details Hidden

FibroGen, Inc. issued Common Stock

Details Hidden

FibroGen, Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onFibroGen, Inc. issued USD Common Stock

Auditor

Advised onFibroGen, Inc. issued USD Common Stock

Underwriter

Advised onFibroGen, Inc. issued USD Common Stock

Associate

Advised onFibroGen, Inc. issued Common Stock

Professional

Advised onFibroGen, Inc. issued USD Common Stock

Legal Advisor

Advised onFibroGen, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Founding Partner at Allen Matkins Leck Gamble Mallory & Natsis LLP

Clients

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$3.98B
Total Enterprise Value
$3.4B
Earnings Per Share
$-1.03
Revenue
$213M
Net Profit
$-86.4M
EBITDA
$-80.1M
EBITDAMargin
-37.63%
Total Debt
$108M
Total Equity
$528M
Enterprise Value Sales
15.95x
TEVNet Income
-39.3x
Debt TEV
0.03x
Investors
Details Hidden

Founded in 1994 by Daniel S. Och, Och-Ziff Capital Management Group is one of the largest institutional alternative asset managers in the world, with approximately $31.9 billion in assets under management as of January 1, 2013. Our funds seek to generate consistent, positive, absolute returns across market cycles with low volatility compared to the equity markets. We have always limited our use of leverage to generate investment performance and we emphasize preservation of capital. We serve the investment needs of a diversified institutional base, providing asset management services through our hedge funds and other alternative investment vehicles, which pursue a broad range of global investment opportunities. We focus on establishing long-term relationships with a global base of institutional investors, which today includes many of the largest, most sophisticated investors in the world. These include pension funds, fund-of-funds, foundations and endowments, corporations and other institutions, private banks and family offices

Details Hidden

Merlin Biomed Group LLC is a venture capital/private equity firm located in New York City

Details Hidden

Sigma Capital Group Plc is a holding company, which engages in the provision of property asset management to residential and commercial properties. It operates through the following segments: Regeneration, Managed Property, Owned PRS Property, Venture Capital, and Holding Company. The company was founded by Graham Fleming Barnet and Neil David Crabb in December 1996 and is headquartered in Edinburgh, the United Kingdom.

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Dana-Farber Cancer Institute, Inc. Biotechnology | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

University of Miami Schools & Student Services | Coral Gables, Florida

The University of Miami is a private research university in Coral Gables, Florida. As of 2019, the university enrolls 17,811 students in 12 separate colleges/schools, including the Leonard M. Miller School of Medicine in Miami's Health District, a law school on the main campus, and the Rosenstiel School of Marine and Atmospheric Science focused on the study of oceanography and atmospheric sciences on Virginia Key, with research facilities at the Richmond Facility in southern Miami-Dade County. The university offers 132 undergraduate, 148 master's, and 67 doctoral degree programs, of which 63 are research/scholarship and four professional areas of study. Over the years, the university's students have represented all 50 states and close to 150 foreign countries. With more than 16,000 full- and part-time faculty and staff, UM is a top 10 employer in Miami-Dade County. UM's main campus in Coral Gables has 239 acres and over 5.7 million square feet of buildings. Research is a component of each academic division, with UM attracting $358.9 million in sponsored research grants in FY 2019. UM offers a large library system with over 3.9 million volumes and exceptional holdings in Cuban heritage and music. UM also offers a wide range of student activities, including fraternities and sororities, a student newspaper and a radio station. UM's intercollegiate athletic teams, collectively known as the Miami Hurricanes, compete in Division I of the National Collegiate Athletic Association. UM's football team has won five national championships since 1983 and its baseball team has won four national championships since 1982.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by FibroGen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of FibroGen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and FibroGen, Inc..